Actuate Therapeutics Inc. (ACTU)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
Analysts see 200%+ upside in these 3 high-risk stocks: here's why?
Some of Wall Street's biggest upside calls are not sitting in the mega-cap names. They are hiding in small, volatile stocks with thin balance sheets, limited operating history and one big event ahead.
Actuate Therapeutics drug improves survival odds in pancreatic cancer trial
Twice as many advanced pancreas cancer patients who received an experimental drug developed by Actuate Therapeutics with chemotherapy were alive after one year as those treated with chemo alone, according to results of a mid-stage trial.
Actuate Therapeutics, Inc. (ACTU) Upgraded to Buy: What Does It Mean for the Stock?
Actuate Therapeutics, Inc. (ACTU) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Actuate Therapeutics Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Bobby Adusumilli SJS Investment Consulting Inc. | 1 | $2.74 | $1.71 | -$1.03 | -37.59% |
 Kevin Kroskey True Wealth Design LLC | 14 | $42.33 | $24.08 | -$18.25 | -43.11% |
| WPA Wealth Preservation Advisors LLC Wealth Preservation Advisors LLC | 7 | $19 | $12.11 | -$6.89 | -36.26% |
 Alexandra Stickelman Root Financial Partners, LLC | 5 | $14 | $8.65 | -$5.35 | -38.21% |
 Christopher C. Powers Farther Finance Advisors, LLC | 7 | $19.18 | $10.08 | -$9.1 | -47.45% |
Actuate Therapeutics Inc. (ACTU) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Actuate Therapeutics Inc. ever had a stock split?
Actuate Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Daniel Schmitt CEO | NASDAQ (NMS) Exchange | 005083100 CUSIP |
| US Country | 12 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a primary focus on developing innovative therapies to treat cancers. Originating as Apotheca Therapeutics, Inc., the company underwent a name change to Actuate Therapeutics, Inc. in October 2015 and has since been working towards the advancement of its cancer treatment portfolio. With its establishment in 2015 and headquarters in Fort Worth, Texas, Actuate Therapeutics is pushing the boundaries of cancer therapy through its dedication to research and development in this critical field.
Products and Services
- Elraglusib Injection
This flagship product candidate from Actuate Therapeutics represents a cutting-edge approach in cancer treatment. As a novel glycogen synthase kinase-3 (GSK-3) inhibitor, Elraglusib Injection is primarily being developed to combat metastatic pancreatic ductal adenocarcinoma. By targeting a crucial signaling pathway involved in cancer cell proliferation and survival, Elraglusib offers a promising option for patients battling this aggressive form of cancer.
- Expansion of Elraglusib's Therapeutic Use
Recognizing the potential of Elraglusib, Actuate Therapeutics is also exploring its applicability in treating other cancer types, including:
- Ewing Sarcoma: A rare but aggressive cancer affecting bones or the soft tissue around the bones, primarily in children and young adults.
- Metastatic Melanoma: An advanced form of skin cancer that has spread to other parts of the body, known for its challenging prognosis.
- Colorectal Cancer: A common form of cancer affecting the colon and rectum, where early detection and treatment are vital for survival.
